Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Tafluprost
Santen UK Ltd
S01EE05
Tafluprost
15microgram/1ml
Eye drops
Ocular
No Controlled Drug Status
Valid as a prescribable product
BNF: 11060000; GTIN: 5013945002225
Saflutan_SD UK [032] 20171122 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT SAFLUTAN® 15 MICROGRAMS/ML EYE DROPS, SOLUTION IN SINGLE DOSE-CONTAINER Tafluprost READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU . Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What SAFLUTAN is and what it is used for 2. What you need to know before you use SAFLUTAN 3. How to use SAFLUTAN 4. Possible side effects 5. How to store SAFLUTAN 6. Contents of the pack and other information 1. WHAT SAFLUTAN IS AND WHAT IT IS USED FOR WHAT KIND OF MEDICINE IS IT AND HOW DOES IT WORK? SAFLUTAN eye drops contain tafluprost, which belongs to a group of medicines called prostaglandin analogues. SAFLUTAN lowers the pressure in the eye. It is used when the pressure in the eye is too high. WHAT IS YOUR MEDICINE FOR? SAFLUTAN is used to treat a type of glaucoma called open angle glaucoma and also a condition known as ocular hypertension in adults. Both of these conditions are linked with an increase in the pressure within your eye and eventually they may affect your eyesight. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE SAFLUTAN DO NOT USE SAFLUTAN: if you are allergic to tafluprost or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor, pharmacist or nurse before using SAFLUTAN. PLEASE NOTE that SAFLUTAN may have the following effects and that some of them may be permanent: SAFLUTAN may increase the length, thickness, colour and/or number of your eyelashes and may cause unusual hair growth on your e Read the complete document
OBJECT 1 SAFLUTAN 15 MICROGRAMS/ML EYE DROPS, SOLUTION, IN SINGLE-DOSE CONTAINER Summary of Product Characteristics Updated 05-Dec-2017 | Santen UK Limited 1. Name of the medicinal product SAFLUTAN 15 micrograms/ml eye drops, solution, in single-dose container. 2. Qualitative and quantitative composition One ml of eye drops, solution, contains 15 micrograms of tafluprost. One single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Eye drops, solution in single-dose container (eye drops). A clear, colourless solution. 4. Clinical particulars 4.1 Therapeutic indications Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. As monotherapy in patients: o who would benefit from preservative free eye drops o insufficiently responsive to first line therapy o intolerant or contra-indicated to first line therapy. As adjunctive therapy to beta-blockers. SAFLUTAN is indicated in adults ≥ 18 years. 4.2 Posology and method of administration Posology The recommended dose is one drop of SAFLUTAN in the conjunctival sac of the affected eye(s) once daily in the evening. The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect. For single use only, one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use. _Use in elderly_ No dosage alteration in elderly patients is necessary. _Paediatric population_ The safety and efficacy of tafluprost in children below age 18 has not yet been established. No data are available. _Use in renal/hepatic impairment_ Tafluprost has not been studied in patients with renal/hepatic impairment and should therefore be used with caution in such patients. Method of administration To reduce the risk of darkening of the eyelid skin the patients should wipe off any excess solutio Read the complete document